Core Viewpoint - The company currently has six innovative drugs in development, focusing on cardiovascular, urological, anti-tumor, and respiratory systems [1] Group 1: Innovative Drug Pipeline - The company has six innovative drugs, with one in Phase III, two in Phase I clinical trials, and three in preclinical research [1] - The drug LH-2103 is undergoing IIT (investigator-initiated trials) and DDI (drug-drug interaction) studies [1] - The drug LH-1801 is in Phase III, having completed patient enrollment for both monotherapy and combination therapy, with ongoing follow-up for both treatment types [1]

Core Viewpoint - The Chinese innovative drug sector is experiencing a resurgence, driven by recent approvals of new drugs, increased market activity, and favorable policy changes, indicating a new growth cycle for the industry [1][2][16]. Group 1: Market Activity - On May 29, the National Medical Products Administration approved 11 innovative drugs, with 10 from listed companies, leading to a surge in stock prices and significant market interest [1]. - Following the approvals, 53 stocks hit the daily limit up in the A-share market, and over 200 million yuan flowed into innovative drug ETFs in Hong Kong over the past 20 trading days [1][2]. - The innovative drug sector, which had been quiet for two years, is now seeing renewed interest from investors, with venture capitalists starting to push more projects for investment decisions [2]. Group 2: Funding Trends - The first quarter of 2025 saw over 20 billion yuan in financing for the innovative drug sector, with at least 19 financing events occurring, indicating a robust recovery in investment [3][4][5]. - Major financing rounds included significant investments in companies focusing on various therapeutic areas, including immunotherapy and gene therapy, showcasing a diverse interest from capital [4]. Group 3: Product Development - In the first five months of this year, over 20 class 1 innovative drugs were approved, marking a record for the past five years [6][7]. - The approval rate for new drugs has significantly increased since the implementation of the new drug registration management measures in 2020, with approvals rising from single digits in previous years to over 30 in recent years [8]. Group 4: Policy Environment - The regulatory environment for innovative drugs in China is continuously improving, with recent reforms aligning more closely with international standards, enhancing the credibility of clinical trial data [11][12]. - The government has implemented a comprehensive support system for innovative drugs, including payment reforms and a multi-layered insurance system, which is expected to facilitate market access and improve commercialization prospects [13][14][15]. Group 5: Future Outlook - The innovative drug sector is poised for a new growth cycle, supported by clinical breakthroughs, international collaborations, and favorable policies, indicating a potential "golden period" for the industry [16].

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company is undergoing a transformation towards innovation, with results expected to materialize soon. The impact of centralized procurement on existing generic and traditional Chinese medicine businesses is gradually diminishing, while the industrial microbiology and medical aesthetics segments are expected to contribute to revenue growth. Overall, the company's performance is projected to grow steadily, and the realization of innovation may lead to a revaluation of its value [7]. - The company has over 80 innovative drug candidates in its pipeline, focusing on endocrine, autoimmune, and oncology fields. The innovative products are expected to be launched and contribute to revenue starting in 2025, enhancing the sales system for innovative drugs [7]. - The industrial microbiology and medical aesthetics segments are forming a diversified growth engine. The company has established a strategic layout in industrial microbiology and is expected to achieve rapid growth as customer orders convert into production capacity. The medical aesthetics segment is also anticipated to recover quickly with the launch of new products [7]. Summary by Sections 1. Company Overview - Established in 1993, the company has developed into a large-scale comprehensive pharmaceutical enterprise covering the entire pharmaceutical industry chain, including pharmaceutical manufacturing, commercial distribution, medical aesthetics, and industrial microbiology [13]. - The company has shifted its focus from generic drug development to innovation-driven strategies since 2018, with a strong emphasis on endocrine, autoimmune, and oncology treatment areas [13]. 2. Financial Performance - The company's total revenue is projected to grow from 40,624 million in 2023 to 52,228 million in 2027, with a compound annual growth rate (CAGR) of 11.64% from 2010 to 2024. The net profit attributable to shareholders is expected to increase from 2,839 million in 2023 to 5,154 million in 2027 [1][20]. - The company's gross profit margin and net profit margin have improved, with gross profit margin rising from 24.27% in 2016 to 33.31% in 2024 [23]. 3. Innovation and R&D - The company has established a comprehensive drug research and development system, focusing on innovative drug candidates in the fields of oncology, endocrine, and autoimmune diseases. The R&D pipeline includes over 80 projects, with significant progress in clinical trials for several innovative products [26][32]. - The company has significantly increased its R&D investment, with the number of researchers growing from 550 in 2018 to 1,864 in 2024, and R&D expenditure rising from 707 million in 2018 to 1,770 million in 2023 [29]. 4. Market Position and Growth Potential - The company is well-positioned in the GLP-1 receptor agonist market, with several innovative products in various stages of clinical development. The global market for GLP-1 drugs is expected to grow significantly, providing a substantial opportunity for the company [39][46]. - The medical aesthetics segment is also expected to contribute to growth, with the company expanding its international and high-end product offerings [7].

Group 1: General Information - The research was conducted on Zhongshan Biovalley Pharmaceutical Co., Ltd. in the traditional Chinese medicine industry on June 9, 2025. The company was represented by board secretary Yang Wei and securities affairs representative Chen Zimin [1][2][8] - Participating research institutions included Ping An Securities Co., Ltd., Shenzhen Chuanghua Qisheng Consulting Co., Ltd., and Far East Horizon [2][9] Group 2: R & D Pipeline - The company has established a multi - mode R & D ecosystem, focusing on metabolic and respiratory diseases. It has 2 approved innovative drugs and multiple projects in clinical trials [14] - In metabolic diseases, ZSP1601 for MASH is in Phase IIb clinical trials. RAY1225 for type 2 diabetes and obesity has completed Phase II trials and is entering Phase III [14][23][24] - In respiratory diseases, oral anti - COVID drug Lairetrievir and anti - influenza drug Enlatavir have been approved. Enlatavir granules for children are in Phase II trials [14][15][16] Group 3: R & D Results - ZSP1601 showed potential in reducing liver inflammation and fibrosis in Ib/IIa trials, with results published in Nature Communications [14] - Lairetrievir's research results are published in top journals, and it is included in the expert consensus for COVID treatment [15] - Enlatavir outperformed placebo and Oseltamivir in Phase III trials, and Enlatavir granules showed positive results in Phase II trials for children [16][17][18] - RAY1225 significantly outperformed placebo in weight loss, blood sugar control, and improving cardiovascular - kidney - metabolic risk factors in Phase II trials [25][26][27] Group 4: Marketing Strategy - The company deepens marketing innovation in three dimensions: academic ecosystem construction, digital service upgrade, and key project implementation for Enlatavir sales [19] Group 5: Asset Impairment - In 2024, the company recorded total asset impairment losses of 546.68 million yuan, reducing net profit and equity by 484.10 million yuan. The main reasons were inventory, goodwill, intangible assets, and R & D project impairments [20] Group 6: Equity Redemption - The company redeemed 13.15% of the equity in its subsidiary Zhongshan Biovalley Innovation from other shareholders for 546 million yuan, increasing its stake to 74.26% [29][30] Group 7: Change of Fund Use - The company plans to change the use of 103.08 million yuan of unused raised funds for the "New Drug R & D Project" of its subsidiary Zhongshan Biovalley Innovation, subject to shareholder approval [30][31]

Group 1: Research Basic Information - The research object is Huasen Pharmaceutical, belonging to the traditional Chinese medicine industry, and the reception time is June 9, 2025. The listed company's reception staff includes Zhou Zhiru, the representative of the securities affairs, and Long Jie, the commissioner of the securities affairs [17] Group 2: Detailed Research Institutions - The research institutions include Zhonggeng Fund (a fund management company) with researcher Li Niuniu, and Guojin Medicine (others) with researcher Wang Benben [18] Group 3: Proportion of Research Institutions - Fund management companies account for 50%, and others account for 50%, with 1 fund management company and 1 other institution [19] Group 4: Core Views - The five key Chinese patent medicines of the company maintained a good growth momentum in 2024 and Q1 2025, and the company focuses on their technology market promotion and access work, especially in non - grade public hospital channels [23] - The company's current sales terminal is mainly public hospitals, accounting for about 70%. It will actively layout the out - of - hospital market to increase its proportion [24] - In May 2025, Huasen Yinuo increased its stake in and controlled Aorui Pharmaceutical, integrating its R & D pipeline, team, and equipment. It now has 7 self - initiated Class 1.1 innovative drug R & D projects, with the most advanced one in clinical Ia/Ib phase [25] - The company's short - and medium - term R & D strategy focuses on product listing, and it has built a "333" pipeline pattern and multiple innovative drug R & D platforms [25][26]

Group 1 - The stock of Zhejiang Anglikang Pharmaceutical Co., Ltd. (stock code: 002940) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days (June 6, 2025, and June 9, 2025) [1] - The company's board of directors conducted an investigation into the abnormal trading situation and confirmed that there were no undisclosed significant information or major changes affecting the company [1][2] - The only ongoing project is ALK-N001, which received clinical trial approval in April 2025 and is currently in Phase I clinical trials, highlighting the long cycle, high investment, and uncertainty associated with innovative drug development [1][2] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange listing rules, nor any significant information that could impact the stock price [2] - The company emphasizes the importance of rational decision-making for investors, given the inherent risks in the long and costly drug development process [2]

Core Viewpoint - The company, Angli Kang (002940.SZ), has experienced significant stock price fluctuations, with a cumulative deviation of over 20% in closing prices over two consecutive trading days, attributed to abnormal trading activity [1] Company Summary - The company confirmed that there are no corrections or supplementary disclosures needed for previously released information, and there have been no significant changes in the internal or external operating environment [1] - The company and its controlling shareholders have not engaged in any stock trading during the period of abnormal price fluctuations [1] - The innovative drug project ALK-N001 is currently in Phase I clinical trials, characterized by a long research and development cycle and substantial investment requirements, indicating potential investment risks for investors [1]

Core Viewpoint - The company, Anglikang (002940), has experienced a significant stock price fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days, indicating abnormal trading activity [1] Company Summary - The only innovative drug project currently under research by the company is ALK-N001, which received approval for clinical trial notification in April 2025 [1] - As of the date of this announcement, ALK-N001 is still in the Phase I clinical trial stage [1] Industry Summary - The research and development of innovative drugs are characterized by long cycles, high investment, and significant uncertainty [1]

[Table_Main] 行业研究|医疗保健 证券研究报告 医疗保健行业周报 2025 年 06 月 09 日 [Table_Title] ASCO 会议召开，创新药迎来重要催化 ——医药生物行业周报（2025.6.2-2025.6.6） [Table_Summary] 报告要点： 医药板块本周小幅跑赢沪深 300 指数 2025 年 6 月 2 日至 6 月 6 日，申万医药生物指数上涨 1.13%，跑赢 沪深 300 指数 0.25pct，在 31 个申万一级行业指数中排名第 17。2025 年初至今，申万医药生物指数上涨 7.81%，跑赢沪深 300 指数 9.36pct， 涨跌幅在 31 个申万一级行业指数中排名第 5。截至 2025 年 6 月 6 日，医药板块估值为 28.02 倍（TTM 整体法，剔除负值），相对于沪 深 300 估值溢价率为 151.44%。 本周易明医药、万邦德和昂利康等表现较好 涨幅排名前十的个股分别为：易明医药（+33.09%）、万邦德 （+32.59%）、昂利康（+30.28%）、新诺威（+21.36%）、海辰药业 （+21.00%）、赛伦生物（+20.48%）、迈威生 ...

Group 1: Company Overview and R&D Pipeline - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has established a multi-modal and healthy R&D ecosystem focusing on metabolic diseases and respiratory diseases, with two innovative drug projects approved for market and several in clinical trials [1] - The innovative drug ZSP1601 for treating metabolic dysfunction-related fatty liver disease (MASH) has completed Phase Ib/IIa clinical trials, showing significant reduction in liver inflammation markers [3][15] - The oral antiviral drug Lurivon (brand name: Le Ru Ling®) received conditional approval in March 2023 and is included in the national medical insurance directory, providing affordable treatment options for patients [3] Group 2: Clinical Trial Results - ZSP1601 has shown potential in improving liver inflammation and fibrosis, with results published in Nature Communications [3][15] - The clinical trial for Lurivon demonstrated effectiveness and safety, particularly for elderly and patients with liver and kidney dysfunction, without requiring dosage adjustments [3] - The innovative drug Anglave (brand name: An Rui Wei®) has shown statistically significant improvement in flu symptom relief compared to placebo, with a median symptom relief time of 38.83 hours [4][8] Group 3: Financial and Asset Management - In 2024, the company recorded an asset impairment loss of CNY 546.68 million, impacting the net profit attributable to shareholders by CNY 484.10 million [12] - The company has made provisions for inventory and goodwill impairment losses totaling CNY 201.68 million due to market conditions and policy impacts [12][14] Group 4: Strategic Initiatives and Future Plans - The company plans to enhance its marketing strategy by integrating academic resources and building a network of experts in respiratory and infectious diseases [11] - The company has increased its stake in its subsidiary Zhongsheng Ruichuang to 74.26%, enhancing control over its operations and R&D capabilities [27] - A change in the use of raised funds has been proposed to accelerate the R&D of innovative drugs, specifically RAY1225 injection and Anglave granules [28][30]